Edgewise Therapeutics reports Q3 2026 results and initiates two cardiovascular trials
Edgewise Therapeutics announced its third‑quarter 2026 financial results and said it will start a Phase 3 study of EDG‑7500 in hypertrophic cardiomyopathy by the end of 2026. The company also reported the first patient dose in the Phase 2 EQUINOX‑HFpEF trial of EDG‑15400 for heart‑failure with preserved ejection fraction. The quarter featured a $1.348 billion gain from the sale of its sevasemten program to Servier, boosting cash and marketable securities to roughly $1.744 billion.
Why it matters
The gain from the sevasemten sale turns a previous loss into a net income of $1.166 billion, strengthening the balance sheet and providing capital for the ongoing cardiovascular programs. Initiating the Phase 3 trial and dosing the Phase 2 study move the two lead candidates closer to potential market approval, which could drive future revenue.
Key facts
- 1Cash, cash equivalents and marketable securities totaled about $1,743.9 million as of September 30, 2026. prnewswire.com
- 2The company recognized a $1.348 billion gain on the sale of the sevasemten program in Q3 2026. prnewswire.com
- 3Edgewise received $1.396 billion in upfront cash proceeds at the closing of the sevasemten sale. prnewswire.com
- 4R&D expenses were $31.6 million for Q3 2026, down from $37.5 million in the same quarter of 2025. prnewswire.com
- 5G&A expenses were $14.6 million for Q3 2026, up from $9.4 million in the same quarter of 2025. prnewswire.com
- 6Net income for Q3 2026 was $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share. prnewswire.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.